Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VeruVERU +0.83%27 Days Payable is 6,161.66 as of Jun. 2026, which is 5842% above its 10-year median of 103.70. GuruFocus rates VERU with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 706 Biotechnology companies, Veru ranks worse than 141642.92% on this metric.
Veru's average Accounts Payable for the
three
months ended in Jun. 2026 was $1.89 Mil. Veru's Cost of Goods Sold for the
three
months ended in Jun. 2026 was $0.03 Mil.
Hence, Veru's Days Payable for the
three
months ended in Jun. 2026 was 6,161.65.
The historical rank and industry rank for Veru's Days Payable or its related term are showing as below:
During the past 13 years, Veru's highest Days Payable was 730.21. The lowest was 36.97. And the median was 103.70.
VERU's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 111.165 * Ranked among companies with meaningful Days Payable only.
Veru's Days Payable
declined
from Jun. 2025 (7,379.70) to Jun. 2026 (6,161.66).
It may suggest that Veruaccelerated paying its suppliers.
The historical data trend for Veru's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Veru's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veru Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Veru's Days Payable distribution charts can be found below:
* The bar in red indicates where Veru's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Veru's Days Payable for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veru (VERU) has a Days Payable of 6,161.66 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Veru and its competitors. This is 5842% above median its historical median of 103.70. Over the past decade, Veru's Days Payable has ranged from 36.97 to 730.21. According to the industry distribution chart, Veru ranks #999999 out of 706 companies in the Biotechnology industry.
Is Veru's Days Payable too high?
Veru's current Days Payable of 6,161.66 is 5842% above median its 10-year median of 103.70. Over the past 10 years, this metric has ranged from a low of 36.97 to a high of 730.21. The Biotechnology industry median Days Payable is 111.17. Veru's value of 6,161.66 is 5442.8% above this industry median. Based on the distribution chart, Veru ranks #999999 out of 706 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Veru has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Veru's Days Payable compare to TVGN and GRCE?
According to the Biotechnology industry distribution chart, Veru ranks #999999 out of 706 companies for Days Payable. This places Veru in the lower half of its industry. The industry median Days Payable is 111.17. Veru's value of 6,161.66 is 5442.8% above this benchmark. Historically, Veru's own Days Payable has ranged from 36.97 to 730.21 over the past decade. While the company's 10-year median is 103.70 vs. the industry median of 111.17, Veru has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.17, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veru's current Days Payable of 6,161.66 is 5442.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Veru and its competitors. For the Biotechnology industry, the median Days Payable is 111.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veru's current Days Payable is 6,161.66, which is 5842% above median its own 10-year median of 103.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veru stock overvalued right now?
Veru (VERU) has a current Days Payable of 6,161.66. The current Days Payable is 6,161.66, which is 5842% above median its 10-year median of 103.70 and 5442.8% above the Biotechnology industry median of 111.17. Veru's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Veru (VERU), the current Days Payable is 6,161.66 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
27GF Score
Get the complete analysis for VERU
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VERU has been successfully added to your 
